Does Rallies show Form 4 insider transactions for ARCT?

Yes. Rallies tracks ARCT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ARCT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ARCT. It does not provide personalized investment advice.

ARCT (Arcturus Therapeutics Holdings Inc. Common Stock) Stock Analysis - Insider Trades

Arcturus Therapeutics Holdings Inc. Common Stock (ARCT) is a publicly traded Healthcare sector company. As of May 21, 2026, ARCT trades at $6.76 with a market cap of $199.81M and a P/E ratio of -2.40. ARCT moved +1.94% today. Year to date, ARCT is +7.06%; over the trailing twelve months it is -46.30%. Its 52-week range spans $5.85 to $25.88. Analyst consensus is buy with an average price target of $18.50. Rallies surfaces ARCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ARCT stock inside the company?

Recent ARCT insider activity includes SASSINE ANDY bought 1.24K, SASSINE ANDY sold 1.24K, Chivukula Pad sold 12.00K, SASSINE ANDY sold 50.00K, and Chivukula Pad sold 114. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ARCT Key Metrics

Key financial metrics for ARCT
Metric	Value
Price	$6.76
Market Cap	$199.81M
P/E Ratio	-2.40
EPS	$-2.83
Dividend Yield	0.00%
52-Week High	$25.88
52-Week Low	$5.85
Volume	202
Avg Volume	0
Revenue (TTM)	$54.71M
Net Income	$-78.67M
Gross Margin	0.00%

Recent ARCT Insider Trades

SASSINE ANDY bought 1.24K (~$20.50K) on Aug 15, 2025.
SASSINE ANDY sold 1.24K (~$20.50K) on Aug 15, 2025.
Chivukula Pad sold 12.00K (~$249.12K) on Oct 15, 2024.
SASSINE ANDY sold 50.00K (~$1.60M) on Jun 12, 2024.
Chivukula Pad sold 114 (~$5.13K) on Jun 5, 2024.

Latest ARCT News

Arcturus Extends Cash Runway to Q2 2028, Initiates 12-Week CF Study with 10mg Dose — Mar 4, 2026
Arcturus Launches 12-Week Phase 2 CF Study at 10 mg, Extends Runway to 2028 — Mar 3, 2026
Arcturus Therapeutics Faces $0.92 EPS Loss Forecast, Citi Cuts Target to $7 — Feb 26, 2026
Arcturus Outlines Inhaled mRNA CF Phase 2b Trial Plans, Secures FDA OTC Talks — Feb 11, 2026
Price Target Cut to $7; Arcturus Starts Phase 1 mRNA Flu Trial — Feb 9, 2026

ARCT Analyst Consensus

10 analysts cover ARCT: 0 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $18.50.

Common questions about ARCT

Who is trading ARCT stock inside the company?: Recent ARCT insider activity includes SASSINE ANDY bought 1.24K, SASSINE ANDY sold 1.24K, Chivukula Pad sold 12.00K, SASSINE ANDY sold 50.00K, and Chivukula Pad sold 114. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ARCT?: Yes. Rallies tracks ARCT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ARCT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ARCT. It does not provide personalized investment advice.